The Lynx Group

ASH 2019 Highlights

Orlando, FL—The emergence of cellular immunotherapy for a broad array of hematologic malignancies was featured prominently at ASH 2019. The development of adoptive therapy with T-cells that target oncologic malignancies was the subject of the E. Donnall Thomas Lecture “The Long Road to Develop Adoptive Therapy with T Cells That Can Effectively Target Acute Myeloid Leukemia (AML) and Other Malignancies,” delivered by Philip Greenberg, MD, Head, Program in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA.
Read Article

Subscribe to
Value-Based Cancer Care

Stay up to date with personalized medicine by subscribing to receive the free VBCC print publication or weekly e‑Newsletter.

I'd like to receive: